AstraZeneca Says Trials on Covid-19 Treatment Confirm Efficacy, Long-Term Prevention
November 18 2021 - 3:15AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Thursday that Phase 3 trials on its AZD7442
antibody combination confirmed that the treatment reduces risk of
developing symptomatic Covid-19.
The pharmaceutical company said the analysis of its continuing
trial evaluating a median six months of participant follow-up
revealed that one dose of AZD7442 showed 83% reduced symptomatic
Covid-19 risk and no severe disease or deaths.
A separate trial in patients with mild-to-moderate Covid-19
showed that a larger dose of AZD7442 reduced risk of severe
Covid-19 or death by 88% compared to placebo, in patients who had
been symptomatic for three days or fewer at the time of the
treatment.
"These compelling results give me confidence that this
long-acting antibody combination can provide my vulnerable patients
with the long-lasting protection they urgently need to finally
return to their everyday lives," Hugh Montgomery, a professor at
University College London and AZD7442 principal investigator,
said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
November 18, 2021 03:00 ET (08:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024